These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

591 related items for PubMed ID: 34484112

  • 1. Cost-Effectiveness of Dipeptidylpeptidase-4 Inhibitors Added to Metformin in Patients With Type 2 Diabetes in China.
    Lin WQ, Cai ZJ, Chen T, Liu MB, Li N, Zheng B.
    Front Endocrinol (Lausanne); 2021; 12():684960. PubMed ID: 34484112
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective.
    Viriato D, Calado F, Gruenberger JB, Ong SH, Carvalho D, Silva-Nunes J, Johal S, Viana R.
    J Med Econ; 2014 Jul; 17(7):499-507. PubMed ID: 24708176
    [Abstract] [Full Text] [Related]

  • 3. Demographic and Clinical Characteristics of Patients With Type 2 Diabetes Mellitus Initiating Dipeptidyl Peptidase 4 Inhibitors: A Retrospective Study of UK General Practice.
    Tebboth A, Lee S, Scowcroft A, Bingham-Gardiner P, Spencer W, Bolodeoku J, Hassan SW.
    Clin Ther; 2016 Aug; 38(8):1825-1832.e15. PubMed ID: 27491279
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis.
    Erhardt W, Bergenheim K, Duprat-Lomon I, McEwan P.
    Clin Drug Investig; 2012 Mar 01; 32(3):189-202. PubMed ID: 22292415
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China.
    Gu S, Deng J, Shi L, Mu Y, Dong H.
    J Med Econ; 2015 Mar 01; 18(10):808-20. PubMed ID: 25950193
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in Sweden.
    Granström O, Bergenheim K, McEwan P, Sennfält K, Henriksson M.
    Prim Care Diabetes; 2012 Jul 01; 6(2):127-36. PubMed ID: 22001114
    [Abstract] [Full Text] [Related]

  • 8. Adherence, Persistence, and Health Care Costs for Patients Receiving Dipeptidyl Peptidase-4 Inhibitors.
    Rascati KL, Worley K, Meah Y, Everhart D.
    J Manag Care Spec Pharm; 2017 Mar 01; 23(3):299-306. PubMed ID: 28230454
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.
    Schwarz B, Gouveia M, Chen J, Nocea G, Jameson K, Cook J, Krishnarajah G, Alemao E, Yin D, Sintonen H.
    Diabetes Obes Metab; 2008 Jun 01; 10 Suppl 1():43-55. PubMed ID: 18435673
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective.
    Charokopou M, McEwan P, Lister S, Callan L, Bergenheim K, Tolley K, Postema R, Townsend R, Roudaut M.
    BMC Health Serv Res; 2015 Nov 05; 15():496. PubMed ID: 26541516
    [Abstract] [Full Text] [Related]

  • 11. Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece.
    Tzanetakos C, Tentolouris N, Kourlaba G, Maniadakis N.
    Clin Drug Investig; 2016 Aug 05; 36(8):649-59. PubMed ID: 27221806
    [Abstract] [Full Text] [Related]

  • 12. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Lingvay I.
    Endocr Pract; 2017 Jul 05; 23(7):831-840. PubMed ID: 28332871
    [Abstract] [Full Text] [Related]

  • 13. Assessment of the Risk of Hospitalization for Heart Failure With Dipeptidyl Peptidase-4 Inhibitors, Saxagliptin, Alogliptin, and Sitagliptin in Patients With Type 2 Diabetes, Using an Alternative Measure to the Hazard Ratio.
    Kaneko M, Narukawa M.
    Ann Pharmacother; 2017 Jul 05; 51(7):570-576. PubMed ID: 28622738
    [Abstract] [Full Text] [Related]

  • 14. Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results.
    Gibbs JP, Fredrickson J, Barbee T, Correa I, Smith B, Lin SL, Gibbs MA.
    J Clin Pharmacol; 2012 Oct 05; 52(10):1494-505. PubMed ID: 22162539
    [Abstract] [Full Text] [Related]

  • 15. DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.
    Bonora E, Cigolini M.
    Nutr Metab Cardiovasc Dis; 2016 Apr 05; 26(4):273-84. PubMed ID: 27038847
    [Abstract] [Full Text] [Related]

  • 16. Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: A disproportionality analysis among high-risk patients.
    Baksh SN, McAdams-DeMarco M, Segal JB, Alexander GC.
    Pharmacoepidemiol Drug Saf; 2018 Jun 05; 27(6):660-667. PubMed ID: 29655237
    [Abstract] [Full Text] [Related]

  • 17. Pharmacoeconomic analysis of DPP-4 inhibitors.
    Teramachi H, Ohta H, Tachi T, Toyoshima M, Mizui T, Goto C, Tsuchiya T.
    Pharmazie; 2013 Nov 05; 68(11):909-15. PubMed ID: 24380242
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes.
    Kwon CS, Seoane-Vazquez E, Rodriguez-Monguio R.
    BMC Health Serv Res; 2018 Feb 01; 18(1):78. PubMed ID: 29391064
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
    Scheen AJ.
    Diabetes Obes Metab; 2010 Aug 01; 12(8):648-58. PubMed ID: 20590741
    [Abstract] [Full Text] [Related]

  • 20. The cost-effectiveness of saxagliptin versus NPH insulin when used in combination with other oral antidiabetes agents in the treatment of type 2 diabetes mellitus in Poland.
    Grzeszczak W, Czupryniak L, Kolasa K, Sciborski C, Lomon ID, McEwan P.
    Diabetes Technol Ther; 2012 Jan 01; 14(1):65-73. PubMed ID: 22066527
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.